COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: PROJECT 4

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 我们先前报道了不同“初免-加强”免疫方案的保护效力的比较研究，所述方案包括用表达HIV-1 SF 162 Env或SIVmac 239 Gag/Pol的重组牛痘或DNA载体初免，随后用DNA、蛋白质或表达相同抗原的异源病毒载体加强。结果显示，无论引发免疫原如何，用蛋白质疫苗加强的动物具有显著更高的抗体滴度，包括同源中和抗体（NtAb）。在SHIVSF 162 P4攻击后，在所有免疫组中观察到平均血浆病毒载量的显著降低。负相关（斯皮尔曼r = -0.819），p10倍，低于那些动物的引发DNA或病毒载体疫苗。直肠内SHIV 162 P4攻击后，蛋白质-DNA或蛋白质-蛋白质初免-加强免疫组中除一只动物外的所有动物均被感染。这些结果进一步支持了引发-加强免疫中的引发在产生针对灵长类慢病毒感染的保护性免疫中的重要作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We previously reported comparative studies of the protective efficacy of different "prime-boost" immunization regimens consisted of priming with recombinant vaccinia or DNA vectors expressing HIV-1 SF162 Env or SIVmac239 Gag/Pol, followed by boosting with DNA, protein; or heterologous viral vector expressing the same antigens. Results showed that, regardless of the priming immunogen, animals boosted with protein vaccines had significantly higher antibody titers, including homologous neutralization antibodies (NtAb). After SHIVSF162P4 challenge, significant reduction of mean plasma viral load was observed in all immunization groups. An inverse correlation (Spearman's r = -0.819), p10-fold less than those achieved by animals that were primed DNA or virus vector vaccines. Following intrarectal SHIV162 P4 challenge, all but one animal in each of the protein-DNA or protein-protein prime-boost groups were infected. These results further support the important role of priming in the prime-boost immunization in the generation of protective immunity against primate lentivirus infection.